Pre-exposure immunization against rabies using Japanese rabies vaccine following the WHO recommended schedule

We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination o...

Full description

Saved in:

Bibliographic Details
Published in	Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 16; no. 1; pp. 38 - 41
Main Authors	Yanagisawa, Naoki, Suganuma, Akihiko, Takayama, Naohide, Nakayama, Eiichi, Mannen, Kazuaki
Format	Journal Article
Language	English
Published	Japan Elsevier Ltd 01.02.2010 Springer Japan
Subjects	Adult Animals Antibodies, Neutralizing - blood Antibodies, Viral - blood Chick Embryo Enzyme-Linked Immunosorbent Assay Female Hematology, Oncology and Palliative Medicine Humans Immunization Immunization Schedule Infectious Diseases Japan Male Medical Microbiology Medicine Medicine & Public Health Middle Aged Original Article Post-exposure prophylaxis Pre-exposure immunization Rabies - prevention & control Rabies - virology Rabies vaccine Rabies Vaccines - administration & dosage Rabies Vaccines - adverse effects Rabies Vaccines - immunology Rabies virus - immunology Virology World Health Organization Young Adult Japan Post-exposure prophylaxis Pre-exposure immunization Rabies vaccine
Online Access	Get full text
ISSN	1341-321X 1437-7780 1437-7780
DOI	10.1007/s10156-009-0019-Y

Cover

Abstract	We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination of enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody (NA) assay. By day 42 of the experiment, which was 2 weeks after the third dose, all subjects had developed NA titers of 0.5IU/ml or higher. The geometric mean titers of ELISA antibody and NA were 3.8EU/ml and 5.7IU/ml, respectively. Overall, the vaccine was well tolerated by all subjects. These results suggest that PCEC-K used for pre-exposure immunization according to the WHO schedule is as immunogenic and effective as the current pre-exposure immunization regimen in Japan, which consists of vaccines administered on days 0, 28, and 180. An accelerated schedule would be of great advantage to Japanese travelers, who could complete the required three doses for primary immunization in 1 month.
AbstractList	We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination of enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody (NA) assay. By day 42 of the experiment, which was 2 weeks after the third dose, all subjects had developed NA titers of 0.5IU/ml or higher. The geometric mean titers of ELISA antibody and NA were 3.8EU/ml and 5.7IU/ml, respectively. Overall, the vaccine was well tolerated by all subjects. These results suggest that PCEC-K used for pre-exposure immunization according to the WHO schedule is as immunogenic and effective as the current pre-exposure immunization regimen in Japan, which consists of vaccines administered on days 0, 28, and 180. An accelerated schedule would be of great advantage to Japanese travelers, who could complete the required three doses for primary immunization in 1 month. We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination of enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody (NA) assay. By day 42 of the experiment, which was 2 weeks after the third dose, all subjects had developed NA titers of 0.5 IU/ml or higher. The geometric mean titers of ELISA antibody and NA were 3.8 EU/ml and 5.7 IU/ml, respectively. Overall, the vaccine was well tolerated by all subjects. These results suggest that PCEC-K used for pre-exposure immunization according to the WHO schedule is as immunogenic and effective as the current pre-exposure immunization regimen in Japan, which consists of vaccines administered on days 0, 28, and 180. An accelerated schedule would be of great advantage to Japanese travelers, who could complete the required three doses for primary immunization in 1 month. We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination of enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody (NA) assay. By day 42 of the experiment, which was 2 weeks after the third dose, all subjects had developed NA titers of 0.5 IU/ml or higher. The geometric mean titers of ELISA antibody and NA were 3.8 EU/ml and 5.7 IU/ml, respectively. Overall, the vaccine was well tolerated by all subjects. These results suggest that PCEC-K used for pre-exposure immunization according to the WHO schedule is as immunogenic and effective as the current pre-exposure immunization regimen in Japan, which consists of vaccines administered on days 0, 28, and 180. An accelerated schedule would be of great advantage to Japanese travelers, who could complete the required three doses for primary immunization in 1 month.We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination of enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody (NA) assay. By day 42 of the experiment, which was 2 weeks after the third dose, all subjects had developed NA titers of 0.5 IU/ml or higher. The geometric mean titers of ELISA antibody and NA were 3.8 EU/ml and 5.7 IU/ml, respectively. Overall, the vaccine was well tolerated by all subjects. These results suggest that PCEC-K used for pre-exposure immunization according to the WHO schedule is as immunogenic and effective as the current pre-exposure immunization regimen in Japan, which consists of vaccines administered on days 0, 28, and 180. An accelerated schedule would be of great advantage to Japanese travelers, who could complete the required three doses for primary immunization in 1 month. Abstract We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination of enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody (NA) assay. By day 42 of the experiment, which was 2 weeks after the third dose, all subjects had developed NA titers of 0.5 IU/ml or higher. The geometric mean titers of ELISA antibody and NA were 3.8 EU/ml and 5.7 IU/ml, respectively. Overall, the vaccine was well tolerated by all subjects. These results suggest that PCEC-K used for pre-exposure immunization according to the WHO schedule is as immunogenic and effective as the current pre-exposure immunization regimen in Japan, which consists of vaccines administered on days 0, 28, and 180. An accelerated schedule would be of great advantage to Japanese travelers, who could complete the required three doses for primary immunization in 1 month. We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended by the WHO. Post-vaccination serum samples were obtained from 53 human subjects, and rabies antibody titers were determined by a combination of enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody (NA) assay. By day 42 of the experiment, which was 2 weeks after the third dose, all subjects had developed NA titers of 0.5 IU/ml or higher. The geometric mean titers of ELISA antibody and NA were 3.8 EU/ml and 5.7 IU/ml, respectively. Overall, the vaccine was well tolerated by all subjects. These results suggest that PCEC-K used for pre-exposure immunization according to the WHO schedule is as immunogenic and effective as the current pre-exposure immunization regimen in Japan, which consists of vaccines administered on days 0, 28, and 180. An accelerated schedule would be of great advantage to Japanese travelers, who could complete the required three doses for primary immunization in 1 month.
Author	Yanagisawa, Naoki Nakayama, Eiichi Suganuma, Akihiko Mannen, Kazuaki Takayama, Naohide
Author_xml	– sequence: 1 givenname: Naoki surname: Yanagisawa fullname: Yanagisawa, Naoki email: naokiy@cick.jp – sequence: 2 givenname: Akihiko surname: Suganuma fullname: Suganuma, Akihiko – sequence: 3 givenname: Naohide surname: Takayama fullname: Takayama, Naohide – sequence: 4 givenname: Eiichi surname: Nakayama fullname: Nakayama, Eiichi – sequence: 5 givenname: Kazuaki surname: Mannen fullname: Mannen, Kazuaki organization: Institute of Scientific Research, Oita University, Oita, Japan
BackLink	https://cir.nii.ac.jp/crid/1570572701281359360$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/20063031$$D View this record in MEDLINE/PubMed
BookMark	eNqNku1r1TAYxYtM3Iv-AX6RfhD8VH2eviVFEGQ4pwwmqOg-hTR5epfZJtek3bz-9aZ2F2GwTUraEn7n5PCc7Cc71llKkqcILxGAvQoIWNUZQBMXNtnZg2QPy4JljHHYif9FiVmR4_fdZD-Ei8iwivNHyW4OUBdQ4F4yfPKU0a-1C5On1AzDZM1vORpnU7mSxoYx9bI1FNIpGLtKP8q1tBRou3splTKW0s71vbuaifGc0m_Hp6kn5YaBrCadBnVOeurpcfKwk32gJ9ffg-Tr0bsvh8fZyen7D4dvTzJV82LMsORtq3TJoSuIlyRBaiyrompQ59B1TVG2tWxBl3nHtMyZhqZrZdVpplFG8CB5sfiuvfs5URjFYIKivo_Z3RQEr5Hx-BT3kqysGELD8v8gyxieYx3JZ9fk1A6kxdqbQfqN2E49AmwBlHcheOqEMuPfoY9eml4giLlfsfQrYr9i7lecRSXeUG7N79LkiyZE1q7Iiws3eRvnf6toE0XPF5E1Jqab31gxqFjOAHOOsYuihoi9XjCKbV6a6B2UIatIm9j_KLQzdyZ7c0Ot-niUkv0P2lD4F1OEXID4PN_n-TojsHmSTTRobje45_A__kH9Yw
CitedBy_id	crossref_primary_10_1371_journal_pone_0287838 crossref_primary_10_11150_kansenshogakuzasshi_84_313 crossref_primary_10_1371_journal_pone_0206717 crossref_primary_10_1007_s10156_011_0286_2 crossref_primary_10_1016_j_tmaid_2013_11_007 crossref_primary_10_3390_v11121118
Cites_doi	10.1111/j.1708-8305.2008.00241.x 10.1007/s10156-007-0573-0 10.1016/j.vaccine.2006.12.012 10.1086/344905 10.1016/S0264-410X(02)00188-3 10.11150/kansenshogakuzasshi1970.82.441
ContentType	Journal Article
Copyright	2010 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2010
Copyright_xml	– notice: 2010 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases – notice: Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases – notice: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2010
DBID	RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8
DOI	10.1007/s10156-009-0019-Y
DatabaseName	CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic
DatabaseTitleList	AIDS and Cancer Research Abstracts MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology Medicine
EISSN	1437-7780
EndPage	41
ExternalDocumentID	20063031 10_1007_s10156_009_0019_Y 10_1007_s10156_009_0019_y 10027189244 S1341321X10706309 1_s2_0_S1341321X10706309
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Japan
GeographicLocations_xml	– name: Japan
GroupedDBID	--- --M -Y2 -~C .1- .55 .86 .FO .~1 0R~ 0VY 1N0 1P~ 1SB 1~. 2.D 28- 29K 2JY 2P1 2VQ 2~H 30V 4.4 408 409 40D 457 4G. 53G 5GY 5QI 5VS 67Z 6NX 7-5 8P~ 8TC 8UJ 95. 95~ AAAJQ AAEDT AAEDW AAIAL AAIKJ AAKOC AALRI AANXM AAOAW AAQFI AARHV AATTM AAXKI AAXUO AAYWO AAYZH ABFSG ABJNI ABMAC ABMNI ABMZM ABQSL ABXDB ACDAQ ACGFS ACIEU ACOMO ACRLP ACSTC ACVFH ADBBV ADCNI ADEZE ADHKG ADIMF ADKPE ADQRH ADRFC ADVLN AEBSH AEFIE AEIPS AEKER AENEX AEUPX AEVXI AEZWR AFBBN AFEXP AFHIU AFLOW AFPUW AFRHN AFTJW AFWTZ AFXIZ AGCQF AGGDS AGHFR AGJBK AGQPQ AGUBO AHBYD AHKAY AHSBF AHWEU AIEXJ AIGII AIIUN AIKHN AITUG AIXLP AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BA0 BBWZM BGNMA BKOJK BLXMC BNPGV CAG CJTIS COF CS3 CSCUP D-I DL5 EBS EFJIC EFKBS EJD EMOBN EN4 F5P FDB FEDTE FIRID FYGXN GBLVA GQ8 GXS H13 HF~ HG5 HG6 HMJXF HVGLF HZ~ I09 IHE IXC IXE IZIGR IZQ I~X KDC KOM KOW KPH LAS M41 M4Y MA- MO0 N2Q N9A NB0 NDZJH NU0 O9- O93 O9G O9I OAM OAUVE OC~ P-8 P-9 P19 P2P P9S PC. PT5 QOK QOS R4E R89 R9I RNI ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SDE SDH SDM SMD SOJ SPCBC SSH SSZ SV3 T13 T16 T5K TSK TSV TT1 TUC U2A VC2 WJK WK8 X7M Z45 Z5R ~A9 ~EX ~G- -5E -5G -BR 0SF AACTN ABTEG ADINQ AFCTW AFKWA AJOXV AMFUW GQ6 NCXOZ RIG SSI SZN Z7U Z82 Z87 Z8O Z8V Z91 AAIAV ABLVK ABYKQ AFNRJ AHPSJ AJBFU EFLBG AGRNS RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8
ID	FETCH-LOGICAL-c683t-148bbcd480f3e84ea0ad1453591d20ff934b6ab0d42f7da27d09fba5fd7d1a453
IEDL.DBID	U2A
ISSN	1341-321X 1437-7780
IngestDate	Mon Sep 08 04:35:08 EDT 2025 Mon Sep 08 14:15:25 EDT 2025 Mon Sep 08 05:45:28 EDT 2025 Wed Feb 19 02:43:25 EST 2025 Thu Apr 24 22:56:41 EDT 2025 Tue Jul 01 02:23:19 EDT 2025 Fri Feb 21 02:33:32 EST 2025 Fri Jun 27 00:58:18 EDT 2025 Fri Feb 23 02:38:59 EST 2024 Sun Feb 23 10:18:48 EST 2025 Tue Aug 26 17:00:12 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Post-exposure prophylaxis Pre-exposure immunization Rabies vaccine
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c683t-148bbcd480f3e84ea0ad1453591d20ff934b6ab0d42f7da27d09fba5fd7d1a453
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	20063031
PQID	744683816
PQPubID	23462
PageCount	4
ParticipantIDs	proquest_miscellaneous_861787873 proquest_miscellaneous_745710972 proquest_miscellaneous_744683816 pubmed_primary_20063031 crossref_citationtrail_10_1007_s10156_009_0019_Y crossref_primary_10_1007_s10156_009_0019_Y springer_journals_10_1007_s10156_009_0019_y nii_cinii_1570572701281359360 elsevier_sciencedirect_doi_10_1007_s10156_009_0019_Y elsevier_clinicalkeyesjournals_1_s2_0_S1341321X10706309 elsevier_clinicalkey_doi_10_1007_s10156_009_0019_Y
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2010-02-01
PublicationDateYYYYMMDD	2010-02-01
PublicationDate_xml	– month: 02 year: 2010 text: 2010-02-01 day: 01
PublicationDecade	2010
PublicationPlace	Japan
PublicationPlace_xml	– name: Japan – name: Netherlands
PublicationSubtitle	Official Journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PublicationTitle	Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
PublicationTitleAbbrev	J Infect Chemother
PublicationTitleAlternate	J Infect Chemother
PublicationTitle_FL	J Infect Chemother
PublicationYear	2010
Publisher	Elsevier Ltd Springer Japan
Publisher_xml	– name: Elsevier Ltd – name: Springer Japan
References	Takahashi, Sagara, Fujita, Hayashi, Yoshida, Inoue (bib0050) 2007; 28 Arai, Kimura, Sakaue, Hamada, Yamada, Nakayama (bib0035) 2002; 20 Feyssaguet, Dacheux, Audry, Compoint, Morize, Blanchard (bib0025) 2007; 25 Takayama (bib0015) 2008; 14 (bib0030) 1996 Takayama, Mannen, Itoda, Kato (bib0040) 2001; 29 WHO expert consultation on rabies: first report. Geneva, Switzerland: World Health Organization; 2005. WHO technical report series no. 931. Yanagisawa, Takayama, Suganuma (bib0020) 2008; 82 Jackson, Warrell, Rupprecht, Ertl, Dietzschold, O’Reilly (bib0005) 2003; 36 Yamamoto, Iwasaki, Oono, Ninomiya, Matsumura (bib0045) 2008; 15 Jackson, Warrell, Rupprecht, Ertl, Dietzschold, O’Reilly (CR1) 2003; 36 Yanagisawa, Takayama, Suganuma (CR4) 2008; 82 CR2 Takayama (CR3) 2008; 14 Takayama, Mannen, Itoda, Kato (CR8) 2001; 29 Yamamoto, Iwasaki, Oono, Ninomiya, Matsumura (CR9) 2008; 15 Arai, Kimura, Sakaue, Hamada, Yamada, Nakayama (CR7) 2002; 20 Takahashi, Sagara, Fujita, Hayashi, Yoshida, Inoue (CR10) 2007; 28 Feyssaguet, Dacheux, Audry, Compoint, Morize, Blanchard (CR5) 2007; 25 (CR6) 1996 Feyssaguet (10.1007/s10156-009-0019-Y_bib0025) 2007; 25 Jackson (10.1007/s10156-009-0019-Y_bib0005) 2003; 36 (10.1007/s10156-009-0019-Y_bib0030) 1996 Takahashi (10.1007/s10156-009-0019-Y_bib0050) 2007; 28 Takayama (10.1007/s10156-009-0019-Y_bib0015) 2008; 14 Takayama (10.1007/s10156-009-0019-Y_bib0040) 2001; 29 10.1007/s10156-009-0019-Y_bib0010 Arai (10.1007/s10156-009-0019-Y_bib0035) 2002; 20 Yanagisawa (10.1007/s10156-009-0019-Y_bib0020) 2008; 82 Yamamoto (10.1007/s10156-009-0019-Y_bib0045) 2008; 15
References_xml	– volume: 20 start-page: 2448 year: 2002 end-page: 2453 ident: bib0035 article-title: Antibody responses induced by immunization with a Japanese rabies vaccine determined by neutralization test and enzyme-linked immunosorbent assay publication-title: Vaccine – volume: 82 start-page: 441 year: 2008 end-page: 444 ident: bib0020 article-title: WHO recommended pre-exposure prophylaxis for rabies using Japanese rabies vaccine (in Japanese) publication-title: Kansenshogaku Zasshi – volume: 29 start-page: 395 year: 2001 end-page: 397 ident: bib0040 article-title: Efficacy of human pre-exposure anti-rabies immunization with simultaneous intradermal and subcutaneous injections (in Japanese) publication-title: Clin Virol – volume: 28 start-page: 64 year: 2007 end-page: 65 ident: bib0050 article-title: Clinical course of the imported rabies case occurred after an interval of 36 years—Yokohama (in Japanese) publication-title: IASR – volume: 25 start-page: 2244 year: 2007 end-page: 2251 ident: bib0025 article-title: Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people publication-title: Vaccine – volume: 15 start-page: 372 year: 2008 end-page: 374 ident: bib0045 article-title: The first imported case of rabies into Japan in 36 years: a forgotten life-threatening disease publication-title: J Travel Med – volume: 14 start-page: 8 year: 2008 end-page: 14 ident: bib0015 article-title: Rabies: a preventable but incurable disease publication-title: J Infect Chemother – volume: 36 start-page: 60 year: 2003 end-page: 63 ident: bib0005 article-title: Management of rabies in humans publication-title: Clin Infect Dis – reference: WHO expert consultation on rabies: first report. Geneva, Switzerland: World Health Organization; 2005. WHO technical report series no. 931. – start-page: 207 year: 1996 end-page: 217 ident: bib0030 publication-title: Rabies, OIE manual of standards for diagnostic tests and vaccines – volume: 29 start-page: 395 year: 2001 end-page: 397 ident: CR8 article-title: Efficacy of human pre-exposure anti-rabies immunization with simultaneous intradermal and subcutaneous injections (in Japanese) publication-title: Clin Virol – volume: 28 start-page: 64 year: 2007 end-page: 65 ident: CR10 article-title: Clinical course of the imported rabies case occurred after an interval of 36 years—Yokohama (in Japanese) publication-title: IASR – volume: 15 start-page: 372 year: 2008 end-page: 374 ident: CR9 article-title: The first imported case of rabies into Japan in 36 years: a forgotten life-threatening disease publication-title: J Travel Med doi: 10.1111/j.1708-8305.2008.00241.x – volume: 14 start-page: 8 year: 2008 end-page: 14 ident: CR3 article-title: Rabies: a preventable but incurable disease publication-title: J Infect Chemother doi: 10.1007/s10156-007-0573-0 – volume: 25 start-page: 2244 year: 2007 end-page: 2251 ident: CR5 article-title: Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people publication-title: Vaccine doi: 10.1016/j.vaccine.2006.12.012 – start-page: 207 year: 1996 end-page: 217 ident: CR6 publication-title: Rabies, OIE manual of standards for diagnostic tests and vaccines – ident: CR2 – volume: 82 start-page: 441 year: 2008 end-page: 444 ident: CR4 article-title: WHO recommended pre-exposure prophylaxis for rabies using Japanese rabies vaccine (in Japanese) publication-title: Kansenshogaku Zasshi – volume: 36 start-page: 60 year: 2003 end-page: 63 ident: CR1 article-title: Management of rabies in humans publication-title: Clin Infect Dis doi: 10.1086/344905 – volume: 20 start-page: 2448 year: 2002 end-page: 2453 ident: CR7 article-title: Antibody responses induced by immunization with a Japanese rabies vaccine determined by neutralization test and enzyme-linked immunosorbent assay publication-title: Vaccine doi: 10.1016/S0264-410X(02)00188-3 – volume: 25 start-page: 2244 year: 2007 ident: 10.1007/s10156-009-0019-Y_bib0025 publication-title: Vaccine doi: 10.1016/j.vaccine.2006.12.012 – volume: 29 start-page: 395 year: 2001 ident: 10.1007/s10156-009-0019-Y_bib0040 article-title: Efficacy of human pre-exposure anti-rabies immunization with simultaneous intradermal and subcutaneous injections (in Japanese) publication-title: Clin Virol – volume: 36 start-page: 60 year: 2003 ident: 10.1007/s10156-009-0019-Y_bib0005 article-title: Management of rabies in humans publication-title: Clin Infect Dis doi: 10.1086/344905 – volume: 28 start-page: 64 year: 2007 ident: 10.1007/s10156-009-0019-Y_bib0050 article-title: Clinical course of the imported rabies case occurred after an interval of 36 years—Yokohama (in Japanese) publication-title: IASR – volume: 20 start-page: 2448 year: 2002 ident: 10.1007/s10156-009-0019-Y_bib0035 article-title: Antibody responses induced by immunization with a Japanese rabies vaccine determined by neutralization test and enzyme-linked immunosorbent assay publication-title: Vaccine doi: 10.1016/S0264-410X(02)00188-3 – ident: 10.1007/s10156-009-0019-Y_bib0010 – volume: 14 start-page: 8 year: 2008 ident: 10.1007/s10156-009-0019-Y_bib0015 article-title: Rabies: a preventable but incurable disease publication-title: J Infect Chemother doi: 10.1007/s10156-007-0573-0 – volume: 82 start-page: 441 year: 2008 ident: 10.1007/s10156-009-0019-Y_bib0020 article-title: WHO recommended pre-exposure prophylaxis for rabies using Japanese rabies vaccine (in Japanese) publication-title: Kansenshogaku Zasshi doi: 10.11150/kansenshogakuzasshi1970.82.441 – start-page: 207 year: 1996 ident: 10.1007/s10156-009-0019-Y_bib0030 – volume: 15 start-page: 372 year: 2008 ident: 10.1007/s10156-009-0019-Y_bib0045 article-title: The first imported case of rabies into Japan in 36 years: a forgotten life-threatening disease publication-title: J Travel Med doi: 10.1111/j.1708-8305.2008.00241.x
SSID	ssj0017588
Score	1.8776793
Snippet	We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as recommended... Abstract We examined the efficacy and safety of the Japanese purified chick embryo cell rabies vaccine (PCEC-K) when administered on days 0, 7, and 28, as...
SourceID	proquest pubmed crossref springer nii elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	38
SubjectTerms	Adult Animals Antibodies, Neutralizing - blood Antibodies, Viral - blood Chick Embryo Enzyme-Linked Immunosorbent Assay Female Hematology, Oncology and Palliative Medicine Humans Immunization Immunization Schedule Infectious Diseases Japan Male Medical Microbiology Medicine Medicine & Public Health Middle Aged Original Article Post-exposure prophylaxis Pre-exposure immunization Rabies - prevention & control Rabies - virology Rabies vaccine Rabies Vaccines - administration & dosage Rabies Vaccines - adverse effects Rabies Vaccines - immunology Rabies virus - immunology Virology World Health Organization Young Adult
SummonAdditionalLinks	– databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LatwwUKQ59VL6rtuk6FByaOOuLMuWfSyhYQm0XWhCNych6xEM2QfrTdO99Ns7I9u7lGS3UAw-iBG2Z8bz0LwIeefBxjc8q2JjQASihop1znRc6oqlZeZyE2YdfvmaDy_E2Tgb75GTvhYG0yo72d_K9CCtu5VBh83BvK4H37EVWcqTMTgw2DgKi_iEkMjrH3-v0zxAO4bZkwgcI3Qf2WzL58B7iUN4ACyd-HKbbnowrev7LNA70dOglE4fk0edNUk_tS_8hOy56VNyNGrbUa-O6fmmuqo5pkd0tGlUvXpGJqOFi92v-QxPCWkdKkXaqkyqr3QNhiNd6ApcaYrZ8Vf0DBQrDqzsV39qg2F56oGXZrcIAdYk_TH8RtHNnkzC6ToF9xnU2bV7Ti5OP5-fDONu_EJs8iJdxuAoVZWxomA-dYVwmmmbiCzNysRy5n2ZiioHklrBvbSaS8tKX-nMW2kTDYAvyP50NnWvCDWwxLgXoAq1SK3XjhcgWI2xmawsyyPCesQr0_UmxxEZ12rTVRlppYBWmIVXqsuIvF9vmbeNOXYB856aqq84BRmpQG3s2iTv2-Sa7i9vVKIarpi6w4kREeudfzHzvx54CIwGCMB7kkkwpbkMoc4U5y6yiNCeBRUIAYzsANVnN42S4NQXGALeBZJh2q3k20EKLBeFK43Iy5bB15jloTdbmkTkQ8_xaoOGLR-0ev1_eHhDHrY5Gpg0dED2l4sbdwim37J6G_7tPzo2UIo priority: 102 providerName: Elsevier
Title	Pre-exposure immunization against rabies using Japanese rabies vaccine following the WHO recommended schedule
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X10706309 https://www.clinicalkey.es/playcontent/1-s2.0-S1341321X10706309 https://dx.doi.org/10.1007/s10156-009-0019-Y https://cir.nii.ac.jp/crid/1570572701281359360 https://link.springer.com/article/10.1007/s10156-009-0019-y https://www.ncbi.nlm.nih.gov/pubmed/20063031 https://www.proquest.com/docview/744683816 https://www.proquest.com/docview/745710972 https://www.proquest.com/docview/861787873
Volume	16
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxNBEB9MC-KLaP3oqQ37IH3Qnuzt3d7HYxBLrLQGbDA-LXu7eyXQJCWXtubFv92Z-0gEk4gE8nDM5sjO7Mxvdr4A3haI8Y2QuW8MqkCyUL6OufYznfMwky421azD84u4P4zORnLU1HGXbbZ7G5KsNPUfxW7oa_jVZT7iEn_ZgX2JrjudxqHorUIHCICr-jdUz34oglEbytz0E9uMUWc6Hm-CnH-FSysrdPoEHjfwkfVqfj-FB256AA_PmwD5ARwP6lbUyxN2ua6sKk_YMRusm1Qvn8FkMHe--3kzoxtCNq6qROqKTKav9BhBI5vrHN1oRpnxV-wMjSoNq2yf3mlDb2QFytHsnigQSbLv_a-MXOzJpLpZZ-g6oym7ds9hePrp8mPfb0Yv-CZOw4WPTlKeGxulvAhdGjnNtQ0iGcossIIXRRZGeYzstJEoEqtFYnlW5FoWNrGBRsIXsDedTd0hMIOPuCgiNIM6Cm2hnUhRqRpjZZJbHnvAWx4o0_Qlp_EY12rdUZnYppBtlIGXqR8evFstuambcuwiFi1jVVttivpRocnYtSjZtMiVzQkvVaBKobj6RnJGYoZuNLUvyzyIVisbEFODk3-98AhlDjeAvgOZIIwWSRXmDGnmIveAtdKoUAFQVAe5PrstVYIOfUrh310kklJuE7GdJKVSUfyEHrysZX21s6LqyxYGHrxvhV-tt2HLH1q--i_q1_CoTsugPKE3sLeY37ojRHuLvAudD7-CLuz3Pn_pX3Srs_4b0F9LhA
linkProvider	Springer Nature
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxNBEF9sBfVFtGo9tXUfpA_ahb3d-3ws0pLWpgZMMD4te_tRAk1Scqma_96Z-0iEJhE5yMMxe0d25mZ-s_NFyAcPGN-IuGDGgApEC8V0wjXLdcFlHrvEVLMOu1dJZxBdDONhU8ddttnubUiy0tR_FbuBr8Gqw3zAJWyxQx4CFshwbMFAnCxDBwCAq_o3UM9MinDYhjLXPWKTMdqZjEbrIOe9cGllhc6ekacNfKQnNb-fkwduskcedZsA-R456tWtqBfHtL-qrCqP6RHtrZpUL16QcW_mmPt9O8UTQjqqqkTqikyqr_UIQCOd6QLcaIqZ8df0AowqDqts7_7UBt9IPcjR9BdSAJKk3ztfKbrY43F1sk7BdQZTduNeksHZaf9zhzWjF5hJMjln4CQVhbFRxr10WeQ01zaMYhnnoRXc-1xGRQLstJHwqdUitTz3hY69TW2ogfAV2Z1MJ-41oQZuceEjMIM6ktZrJzJQqsbYOC0sTwLCWx4o0_Qlx_EYN2rVURnZpoBtmIGXqx8B-bhccls35dhGLFrGqrbaFPSjApOxbVG6bpErmy-8VKEqheLqG8oZihm40di-LA9ItFzZgJganPzrhQcgc7AB-BvGKcBokVZhTokzF3lAaCuNChQARnWA69O7UqXg0GcY_t1GEmPKbSo2k2RYKgqXDMh-LevLnRVVXzYZBuRTK_xqtQ0b_tDizX9RvyePO_3upbo8v_ryljypUzQwZ-gd2Z3P7twBIL95cVh96X8AcgNL6w
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZbxMxELZokSpeUClHl1LwA-oD1KrX3vOxAqJQaIlEI8KT5fVRRWoOZVMg_56ZPRIkkiC0Uh5W413FMzvzjeci5LUHjG9EXDBjQAWihWI64ZrluuAyj11iqlmHl1dJtx9dDOJBM-e0bLPd25BkXdOAXZrG87Op9Wd_FL6B38Gqg33AKGyxQ-6DNg5R0PvifBlGADBc1cKBqmZShIM2rLnuEZsM0854OFwHP_8KnVYWqbNPHjZQkp7XvH9E7rnxAdm7bILlB-SkV7elXpzS61WVVXlKT2hv1bB68ZiMejPH3K_pBE8L6bCqGKmrM6m-0UMAkHSmC3CpKWbJ39ALMLA4uLK9-0MbfCP1IFOTn0gBqJJ-636h6G6PRtUpOwU3GszarXtC-p0P1--6rBnDwEySyTkDh6kojI0y7qXLIqe5tmEUyzgPreDe5zIqEmCtjYRPrRap5bkvdOxtakMNhE_J7ngydoeEGrjFhY_AJOpIWq-dyEDBGmPjtLA8CQhveaBM06McR2XcqlV3ZWSbArZhNl6uvgfkzXLJtG7QsY1YtIxVbeUp6EoF5mPbonTdIlc2X3upQlUKxdVXlDMUM3CpsZVZHpBoubIBNDVQ-dcLj0HmYAPwN4xTgNQirUKeEucv8oDQVhoVKAOM8ADXJ3elSsG5zzAUvI0kxvTbVGwmybBsFC4ZkGe1rC93VlQ92mQYkLet8KvVNmz4Q4vn_0X9iuz13nfU549Xn47IgzpbA9OHXpDd-ezOHQMInBcvqw_9N_YDUCc
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pre-exposure+immunization+against+rabies+using+Japanese+rabies+vaccine+following+the+WHO+recommended+schedule&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Yanagisawa%2C+Naoki&rft.au=Takayama%2C+Naohide&rft.au=Nakayama%2C+Eiichi&rft.au=Mannen%2C+Kazuaki&rft.date=2010-02-01&rft.issn=1437-7780&rft.eissn=1437-7780&rft.volume=16&rft.issue=1&rft.spage=38&rft_id=info:doi/10.1007%2Fs10156-009-0019-y&rft.externalDBID=NO_FULL_TEXT
thumbnail_m	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F1341321X%2FS1341321X10X70258%2Fcov150h.gif